These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11128 related articles for article (PubMed ID: 1586984)

  • 1. A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma.
    Jones AL; O'Brien ME; Lorentzos A; Viner C; Hanrahan A; Moore J; Millar JL; Gore ME
    Cancer Chemother Pharmacol; 1992; 30(1):73-6. PubMed ID: 1586984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.
    Jones AL; Millar JL; Millar BC; Powell B; Selby P; Winkley A; Lakhani S; Gore ME; McElwain TJ
    Br J Cancer; 1990 Nov; 62(5):776-80. PubMed ID: 2245169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of recombinant leukocyte A interferon (IFN-alpha 2A) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the combination cimetidine with BCNU in patients with disseminated malignant melanoma.
    Morton RF; Creagan ET; Schaid DJ; Kardinal CG; McCormack GW; McHale MS; Wiesenfeld M
    Am J Clin Oncol; 1991 Apr; 14(2):152-5. PubMed ID: 2028922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
    Stark JJ; Dillman RO; Schulof R; Wiemann MC; Barth NM; Honeycutt PJ; Soori G
    Cancer; 1998 May; 82(9):1677-81. PubMed ID: 9576288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
    Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
    J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.
    Creagan ET; Schutt AJ; Long HJ; Green SJ
    Med Pediatr Oncol; 1986; 14(2):86-7. PubMed ID: 3713642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase.
    Smith DC; Gerson SL; Liu L; Donnelly S; Day R; Trump DL; Kirkwood JM
    Clin Cancer Res; 1996 Jul; 2(7):1129-34. PubMed ID: 9816278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
    J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
    Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
    J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
    Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
    Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin.
    Nathanson L; Meelu MA; Losada R
    Cancer; 1994 Jan; 73(1):98-102. PubMed ID: 8275444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
    Richards JM; Mehta N; Ramming K; Skosey P
    J Clin Oncol; 1992 Aug; 10(8):1338-43. PubMed ID: 1634924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
    Kettelhack C; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
    Rajkumar SV; Buckner JC; Schomberg PJ; Pitot HC; Ingle JN; Cascino TL
    Neurosurgery; 1999 Jan; 44(1):67-73. PubMed ID: 9894965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of dibromodulcitol and BCNU in metastatic malignant melanoma.
    Clamon G; Sinkey C; Jochimsen P
    Am J Clin Oncol; 1985 Jun; 8(3):244-6. PubMed ID: 4050743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.
    Eton O; Talpaz M; Lee KH; Rothberg JM; Brell JM; Benjamin RS
    Cancer; 1996 Mar; 77(5):893-9. PubMed ID: 8608480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 557.